<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2019.99166</article-id><article-id pub-id-type="publisher-id">ACM-32195</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20190900000_45865386.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  他克莫司对肾病综合征型紫癜性肾炎的治疗观察
  Treatment of Tacrolimus on Nephrotic Syndrome with Henoch-Schonlein Purpura Nephritis
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>晓玲</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>懿林</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属临沂市人民医院儿内三科，山东 临沂</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>28</day><month>08</month><year>2019</year></pub-date><volume>09</volume><issue>09</issue><fpage>1080</fpage><lpage>1084</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   目的：评价他克莫司(FK506)治疗儿童肾病综合征型紫癜性肾炎(HSPN)的疗效和安全性。方法：选取符合入选标准的43例患儿，应用FK506联合激素治疗，分别于治疗前和治疗后1、2、3月观察各项指标变化，包括24 h尿蛋白定量、尿素氮(BUN)、血肌酐(Scr)、血清白蛋白(Alb)及总胆固醇(TC)。结果：治疗后各项临床生化指标明显改善，差异均有统计学意义(P &lt; 0.05)，且随着治疗时间延长，改善程度越明显。轻度胃肠道反应7例，腹泻3例，均于1周内消失；肝功能异常1例，FK506减量后肝功能恢复正常。结论：FK506联合激素治疗肾病综合征型HSPN，可以减少蛋白尿、降低高血脂，多数得到缓解，认为此治疗取得了明显疗效，且安全性较好。 Objective: To evaluate the efficacy and safety of tacrolimus in the treatment of nephrotic syndrome with Henoch-Schonlein purpura nephritis in children. Methods: 43 children who met the inclusion criteria were selected and treated with the tacrolimus and steroid combination therapy. The indicators were tested before treatment and 3 months later, including the 24 h urinary protein excretion, blood urea nitrogen (BUN), serum creatinine (Scr), plasma albumin (Alb) and total cholesterol (TC). Results: Tacrolimus combined with steroid therapy had significant effects. The clinical and biochemical indicators improved significantly after treatment (P &lt; 0.05), and with the treatment time, the degree of improvement was more obvious. Mild gastrointestinal reaction oc-curred in 4 cases and diarrhea in 2 cases, all disappeared within 1 week. Liver dysfunction occurred in 1 case, and the function returned to normal with drug dose reduction. Conclusion: The tacrolimus and steroid combination therapy for nephrotic syndrome with Henoch-Schonlein purpura nephritis can reduce proteinuria and high cholesterol; and the majority of children get complete remission. This combined treatment has achieved significant efficacy and better safety. 
  
 
</p></abstract><kwd-group><kwd>他克莫司，紫癜性肾炎，激素，儿童, Tacrolimus</kwd><kwd> Henoch-Schonlein Purpura Nephritis</kwd><kwd> Hormone</kwd><kwd> Child</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>他克莫司对肾病综合征型紫癜性肾炎的 治疗观察<sup> </sup></title><p>李晓玲<sup>*</sup>，王懿林<sup>#</sup></p><p>青岛大学附属临沂市人民医院儿内三科，山东 临沂</p><disp-formula id="hanspub.32195-formula33"><graphic xlink:href="//html.hanspub.org/file/6-1571031x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2019年9月1日；录用日期：2019年9月11日；发布日期：2019年9月18日</p><disp-formula id="hanspub.32195-formula34"><graphic xlink:href="//html.hanspub.org/file/6-1571031x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：评价他克莫司(FK506)治疗儿童肾病综合征型紫癜性肾炎(HSPN)的疗效和安全性。方法：选取符合入选标准的43例患儿，应用FK506联合激素治疗，分别于治疗前和治疗后1、2、3月观察各项指标变化，包括24 h尿蛋白定量、尿素氮(BUN)、血肌酐(Scr)、血清白蛋白(Alb)及总胆固醇(TC)。结果：治疗后各项临床生化指标明显改善，差异均有统计学意义(P &lt; 0.05)，且随着治疗时间延长，改善程度越明显。轻度胃肠道反应7例，腹泻3例，均于1周内消失；肝功能异常1例，FK506减量后肝功能恢复正常。结论：FK506联合激素治疗肾病综合征型HSPN，可以减少蛋白尿、降低高血脂，多数得到缓解，认为此治疗取得了明显疗效，且安全性较好。</p><p>关键词 :他克莫司，紫癜性肾炎，激素，儿童</p><disp-formula id="hanspub.32195-formula35"><graphic xlink:href="//html.hanspub.org/file/6-1571031x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/6-1571031x8_hanspub.png" /> <img src="//html.hanspub.org/file/6-1571031x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>紫癜性肾炎(Henoch-Schonlein purpura nephritis, HSPN)是过敏性紫癜(Henoch-Schonlein purpura, HSP)引起的继发性肾脏病，临床表现为血尿和蛋白尿，部分伴有高血压和肾功能不全，多数发生在HSP病程6个月内 [<xref ref-type="bibr" rid="hanspub.32195-ref1">1</xref>] 。目前治疗上常用激素和免疫抑制剂，其中常用免疫抑制剂有环磷酰胺、硫唑嘌呤、环孢素等，但应用过程中均会出现不同程度的不良反应。</p><p>他克莫司(Tacrolimus, Tac)又称FK506，是一种新开发的、更为安全的免疫抑制剂，因其具有强大的免疫抑制功能、不良反应小而广泛应用于临床。我科从2014年6月以来使用FK506治疗肾病综合征型紫癜性肾炎患儿，取得较好的疗效。</p></sec><sec id="s4"><title>2. 资料与方法</title><sec id="s4_1"><title>2.1. 一般资料</title><p>本组43例为2014年6月~2017年12月我科门诊和病房患者，年龄2.3~14岁，平均年龄6.3岁，男26例，女17例。同时满足以下入选标准1) 符合儿童常见肾脏疾病诊治循证指南：紫癜性肾炎的诊治循证指南 [<xref ref-type="bibr" rid="hanspub.32195-ref2">2</xref>] ；2) 符合中华医学会儿科学分会肾脏病学组制定的肾病综合征诊断标准 [<xref ref-type="bibr" rid="hanspub.32195-ref3">3</xref>] ；3) 经3个月以上糖皮质激素加环磷酰胺或环孢素标准治疗无效或复发；4) 排除标准：严重感染、中枢神经系统疾病、肝功能异常、糖代谢异常、对大环内酯类药物过敏。</p></sec><sec id="s4_2"><title>2.2. 给药方法</title><p>糖皮质激素剂量：1 mg/kg，每日顿服，联合FK506同时服用，至尿蛋白正常2周后逐渐减量(每2~4周减5 mg)，至0.5 mg/kg，隔日顿服维持。</p><p>FK506首次剂量0.1 mg/(kg.d)，分2次于餐前1 h服用，服用1周后监测有效血药物浓度，以后每月监测FK506浓度，要求维持血浓度5~10 ng/ml。有效者缓解后维持用药1~2月后逐渐减量，总疗程6~24月。</p><p>治疗过程中出现以下情况，需要调整剂量：1) 如血药浓度偏低，增加0.025~0.05 mg/kg，最大剂量不超过0.15 mg/(kg.d)；如血药浓度偏高，不良反应危险性增加，减少0.025~0.05 mg/kg。2) 若服用过程中出现肾功能恶化(Scr上升≥30%)，FK506剂量减少30%，2周后复查肾功能无好转，则停药；3) 若出现白细胞减少：WBC &lt; 3 &#215; 10<sup>9</sup>/L但&gt;2 &#215; 10<sup>9</sup>/L，减半量，1周后不能恢复则停药。WBC &lt; 2 &#215; 10<sup>9</sup>/L，或中性粒细胞绝对值 &lt; 1 &#215; 10<sup>9</sup>/L，暂时停药，如不能恢复则退出；4) 如出现高血糖，则调整剂量和(或)使用降糖药物治疗；5) 出现严重感染或其它不能解释的严重合并症时退出实验。</p></sec><sec id="s4_3"><title>2.3. 观察项目</title><p>观察应用FK506治疗前和治疗后3月的临床指标：浮肿、尿量变化、胃肠道反应及皮疹等；分别于治疗前和治疗后1、2、3月观察生化指标：尿常规、24 h尿蛋白定量、尿素氮(blood urea nitrogen, BUN)、血肌酐(serum creatinine, Scr)、血清白蛋白(plasma albumin, Alb)及总胆固醇(total cholesterol, TC)。</p></sec><sec id="s4_4"><title>2.4. 疗效判定标准 [<xref ref-type="bibr" rid="hanspub.32195-ref2">2</xref>]</title><p>1) 完全缓解：FK506治疗后，血生化及尿常规完全正常；2) 部分缓解：临床症状和体征好转，尿蛋白 &lt; (3+)，24 h尿蛋白 &lt; 50 mg/(kg.d)；3) 无效：临床症状和体征无好转，FK506血药浓度在有效浓度范围内，尿蛋白 &gt; (3+)。</p></sec><sec id="s4_5"><title>2.5. 统计学方法</title><p>应用SPSS17.0统计学软件进行数据处理，数据用均数&#177;标准差( x &#175; &#177; S )表示，多组间均数比较采用单因素方差分析，计数资料比较采用卡方检验，计量资料比较采用t检验。P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. 临床疗效</title><p>43例患儿经FK506治疗后，完全缓解者30例，部分缓解8例，总缓解率88.4%，显效时间9~45天。</p></sec><sec id="s5_2"><title>3.2. 尿蛋白变化</title><p>患儿经FK506治疗后，24 h尿蛋白定量明显下降，且随着治疗时间延长，下降程度越明显(表1)。</p></sec><sec id="s5_3"><title>3.3. 生化指标变化</title><p>FK506治疗后，血液生化指标明显改善(Alb升高，TC降低，BUN降低，Scr降低)，且随着治疗时间延长，改善程度越明显(表1)。</p></sec><sec id="s5_4"><title>3.4. 不良反应</title><p>7例患儿出现轻度胃肠道反应，表现为恶心呕吐4例，腹泻3例，均于1周内消失；1例患儿出现肝功能异常，FK506减量后肝功能恢复正常。</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>紫癜性肾炎是过敏性紫癜最严重的并发症之一，若蛋白质丢失过多，表现为肾病综合征，是紫癜性肾炎常见的一种病理类型，临床表现为大量蛋白尿、低蛋白血症、浮肿、高脂血症等，临床治疗过程中病情易反复，蛋白尿消退缓慢。既往多采用环磷酰胺或环孢素联合小剂量激素治疗，但长期应用存在明显的不良反应，可引起骨髓抑制、出血性膀胱炎、肝功能损害、继发性恶性肿瘤，性腺抑制等。他克莫司(FK506)，从链霉素中提取出来，是一种新型钙调神经磷酸酶抑制剂，属免疫抑制性大环内酯类药物，其作用机制和环孢素相似，但生物学效应是环孢素的10~100倍，具有以下独特优点 [<xref ref-type="bibr" rid="hanspub.32195-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.32195-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.32195-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.32195-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.32195-ref8">8</xref>] ：1) 抑制白细胞介素(interleukin, IL)-5、IL-7等诱发T细胞增殖；2) 产生激素样效应或减少激素用量；3) 显著下调激素蛋白酶组织抑制剂(tissue inhibitor of hormone protein, TIMP)-1表达，减轻组织纤维化；4) 抑制血小板集聚，减少动脉血栓形成和血小板活化诱发的炎症反应。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Changes of laboratory indexes before and after treatment on nephrotic syndrome with HSPN in children ( x &#175; &#177; S </title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >24h尿蛋白定量 (mg/24h)</th><th align="center" valign="middle" >血清白蛋白(g/L)</th><th align="center" valign="middle" >总胆固醇 (mmol/L)</th><th align="center" valign="middle" >尿素氮(mmol/L)</th><th align="center" valign="middle" >血肌酐(umol/L)</th></tr></thead><tr><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >4205.4 &#177; 41.2</td><td align="center" valign="middle" >18.4 &#177; 5.8</td><td align="center" valign="middle" >6.8 &#177; 1.1</td><td align="center" valign="middle" >17.5 &#177; 3.7</td><td align="center" valign="middle" >156.2 &#177; 53.5</td></tr><tr><td align="center" valign="middle" >治疗后1月</td><td align="center" valign="middle" >2043.6 &#177; 38.5<sup>a</sup></td><td align="center" valign="middle" >28.1 &#177; 4.5<sup>a</sup></td><td align="center" valign="middle" >4.8 &#177; 0.8<sup>a</sup></td><td align="center" valign="middle" >9.8 &#177; 4.3<sup>a</sup></td><td align="center" valign="middle" >118.7 &#177; 38.7<sup>a</sup></td></tr><tr><td align="center" valign="middle" >治疗后2月</td><td align="center" valign="middle" >835.6 &#177; 19.8<sup>b</sup></td><td align="center" valign="middle" >32.5 &#177; 4.2<sup>b</sup></td><td align="center" valign="middle" >3.5 &#177; 1.1<sup>b</sup></td><td align="center" valign="middle" >6.3 &#177; 2.6<sup>b</sup></td><td align="center" valign="middle" >102.2 &#177; 29.4<sup>b</sup></td></tr><tr><td align="center" valign="middle" >治疗后3月</td><td align="center" valign="middle" >388.8 &#177; 23.4<sup>b,c</sup></td><td align="center" valign="middle" >45.3 &#177; 3.5<sup>b,c</sup></td><td align="center" valign="middle" >2.7 &#177; 1.3<sup>b,c</sup></td><td align="center" valign="middle" >5.7 &#177; 2.1<sup>b,c</sup></td><td align="center" valign="middle" >80.5 &#177; 25.3<sup>b,c</sup></td></tr><tr><td align="center" valign="middle" >F</td><td align="center" valign="middle" >15.44</td><td align="center" valign="middle" >6.12</td><td align="center" valign="middle" >5.76</td><td align="center" valign="middle" >9.97</td><td align="center" valign="middle" >6.55</td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" >&lt;0.05</td><td align="center" valign="middle" >&lt;0.05</td><td align="center" valign="middle" >&lt;0.05</td><td align="center" valign="middle" >&lt;0.05</td><td align="center" valign="middle" >&lt;0.05</td></tr></tbody></table></table-wrap><p>表1. 肾病综合征型紫癜性肾炎患儿治疗前后实验室指标的变化( x &#175; &#177; S )</p><p>与治疗前组比较，<sup>a</sup>P &gt; 0.05；与治疗后1月组比较，<sup>b</sup>p &lt; 0.05；与治疗后2月组比较，<sup>c</sup>p &lt; 0.05。<sup> </sup></p><p>Compared with the group of before treatment, t = 0.21, 0.87, 0.15, 0.76, 0.34, <sup>a</sup>P &gt; 0.05; Compared with the group of 1month after treatment group, t = 12.80, 11.97, 13.44, 14.71, 16.08, 29.04, 10.92, 13.46, 16.97, 15.86, <sup>b</sup>p &lt; 0.05; Compared with the group of 2month after treatment group, t = 8.37, 4.02, 15.87, 5.44, 6.13, 11.27, <sup>c</sup>p &lt; 0.05.</p><p>FK506可通过干扰钙依赖性信号传导途径，抑制免疫炎症反应，减少肾小球损伤，从而达到降低尿蛋白的效应 [<xref ref-type="bibr" rid="hanspub.32195-ref9">9</xref>] [<xref ref-type="bibr" rid="hanspub.32195-ref10">10</xref>] [<xref ref-type="bibr" rid="hanspub.32195-ref11">11</xref>] 。本研究显示经FK506联合激素治疗后，患儿尿蛋白均逐渐减少，血液生化指标明显改善(Alb升高，TC降低，BUN降低，Scr降低)。在治疗过程中，21.2%患儿出现恶心呕吐等轻微的胃肠道反应，3%患儿出现肝功能异常，药物减量后恢复正常，此结果显示FK506治疗是安全的且耐受性较好。</p><p>综上所述，FK506对于肾病综合征型紫癜性肾炎治疗取得了较满意疗效，有效率高、耐受良好且副作用轻微，是一种具有良好前景的新型免疫抑制剂。由于病例例数较少，需继续随访，增加病例进一步验证。</p></sec><sec id="s7"><title>文章引用</title><p>李晓玲,王懿林. 他克莫司对肾病综合征型紫癜性肾炎的治疗观察Treatment of Tacrolimus on Nephrotic Syndrome with Henoch-Schonlein Purpura Nephritis[J]. 临床医学进展, 2019, 09(09): 1080-1084. https://doi.org/10.12677/ACM.2019.99166</p></sec><sec id="s8"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.32195-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Narchi, H. (2005) Risk of Long Term Renal Impairment and Duration of Follow up Recommended for Henoch-Schonlein Purpura with Normal or Minimal Urinary Findings: A Systematic Review. Archives of Disease in Childhood, 90, 916-920. &lt;br&gt;https://doi.org/10.1136/adc.2005.074641</mixed-citation></ref><ref id="hanspub.32195-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会儿科学分会肾脏病学组. 儿童常见肾脏疾病诊治循证指南(二): 紫癜性肾炎的诊治循证指南[J]. 中华儿科杂志, 2009, 47(12): 911-913.</mixed-citation></ref><ref id="hanspub.32195-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会儿科学分会肾脏病学组. 小儿肾小球疾病的临床分类、诊断及治疗[J]. 中华儿科杂志, 2001, 39(12): 746-747.</mixed-citation></ref><ref id="hanspub.32195-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Butani, L. and Ramsamooj, R. (2009) Experience with Tacrolimus in Children with Steroid-Resistant Nephrotic Syndrome. Pediatric Nephrology, 24, 1517-1523. &lt;br&gt;https://doi.org/10.1007/s00467-009-1220-z</mixed-citation></ref><ref id="hanspub.32195-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Sikma, M.A., Hunault, C.C., van de Graaf, E.A., Verhaar, M.C., et al. (2017) High Tacrolimus Blood Concentrations Early after Lung Transplantation and the Risk of Kidney Injury. European Journal of Clinical Pharmacology, 73, 573-580. &lt;br&gt;https://doi.org/10.1007/s00228-017-2204-8</mixed-citation></ref><ref id="hanspub.32195-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Juul Madsen, M., Bergmann, T.K., Brøsen, K. and Charlotte Thiesson, H. (2017) The Pharmacogenetics of Tacrolimus in Corticosteroid-Sparse Pediatric and Adult Kidney Trans-plant Recipients. Drugs in R &amp; D, 17, 279-286.  
&lt;br&gt;https://doi.org/10.1007/s40268-017-0177-9</mixed-citation></ref><ref id="hanspub.32195-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Thölking, G., Ulrich Gerth, H., Schuette-Nuetgen, K. and Reuter, S. (2017) Influence of Tacrolimus Metabolism Rate on Renal Function after Solid Organ Transplantation. World Journal of Transplantation, 7, 26-33.  
&lt;br&gt;https://doi.org/10.5500/wjt.v7.i1.26</mixed-citation></ref><ref id="hanspub.32195-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Kraaij, T., Bredewold, O.W., Trompet, S., et al. (2016) TAC-TIC Use of Tacroli-mus-Based Regimens in Lupus Nephritis. Lupus Science &amp; Medicine, 3, e000169. &lt;br&gt;https://doi.org/10.1136/lupus-2016-000169</mixed-citation></ref><ref id="hanspub.32195-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Jeong, M., Jang, E., Choi, S.S., et al. (2017) The Function of FK506-Binding Protein 13 in Protein Quality Control Protects Plasma Cells from Endoplasmic Reticulum Stress-Associated Apoptosis. Frontiers in Immunology, 8, 222. 
&lt;br&gt;https://doi.org/10.3389/fimmu.2017.00222</mixed-citation></ref><ref id="hanspub.32195-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Jo, H.S., Eum, W.S., Park, E.Y., et al. (2017) Effects of PEP-1-FK506BP on Cyst Formation in Polycystic Kidney Disease. BMB Reports, 50, 460-465. &lt;br&gt;https://doi.org/10.5483/BMBRep.2017.50.9.090</mixed-citation></ref><ref id="hanspub.32195-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Balan, M., Chakraborty, S., Flynn, E., Zurakowski, D. and Pal, S. (2017) Honokiol Inhibits c-Met-HO-1 Tumor-Promoting Pathway and Its Cross-Talk with Calcineurin Inhibitor-Mediated Renal Cancer Growth. Scientific Reports, 7, 5900. &lt;br&gt;https://doi.org/10.1038/s41598-017-05455-1</mixed-citation></ref></ref-list></back></article>